Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)

RSS

telmisartan

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Kinzalmono. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.

This EPAR was last updated on 27/04/2018

Authorisation details

Product details
Name
Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)
Agency product number
EMEA/H/C/000211
Active substance
telmisartan
International non-proprietary name (INN) or common name
telmisartan
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09CA07
Publication details
Marketing-authorisation holder
Bayer AG
Revision
29
Date of issue of marketing authorisation valid throughout the European Union
16/12/1998
Contact address
51368 Leverkusen
Germany

Product information

04/04/2018 Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) - EMEA/H/C/000211 - T/0111

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin angiotensin system

Therapeutic indication

Hypertension

Treatment of essential hypertension in adults.

Cardiovascular prevention

Reduction of cardiovascular morbidity in patients with:

  • manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;
  • type-2 diabetes mellitus with documented target-organ damage.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating